Trials / Completed
CompletedNCT01633788
A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 232 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of AGN-195263 compared to vehicle in patients with meibomian gland dysfunction (MGD) in the eyelids.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGN-195263 0.1% | 1 drop of AGN-195263 0.1% instilled in each eye twice daily. |
| DRUG | AGN-195263 0.03% | 1 drop of AGN-195263 0.03% instilled in each eye twice daily. |
| DRUG | AGN-195263 0.01% | 1 drop of AGN-195263 0.01% instilled in each eye twice daily. |
| DRUG | AGN-195263 Vehicle | 1 drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily. |
Timeline
- Start date
- 2012-08-22
- Primary completion
- 2015-02-05
- Completion
- 2015-02-05
- First posted
- 2012-07-04
- Last updated
- 2017-09-08
- Results posted
- 2017-09-08
Locations
33 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01633788. Inclusion in this directory is not an endorsement.